ALBERT

All Library Books, journals and Electronic Records Telegrafenberg

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Publication Date: 2014-01-17
    Description: The traditional Chinese medical compound Rocaglamide protects nonmalignant primary cells from DNA damage-induced toxicity by inhibition of p53 expression Cell Death and Disease 5, e1000 (January 2014). doi:10.1038/cddis.2013.528 Authors: M S Becker, P Schmezer, R Breuer, S F Haas, M A Essers, P H Krammer & M Li-Weber
    Keywords: chemoprotectionp53apoptosisRocaglamideanticancer drugTCM
    Electronic ISSN: 2041-4889
    Topics: Biology , Medicine
    Published by Springer Nature
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 2
    Publication Date: 2009-02-13
    Description: Maintenance of the blood system is dependent on dormant haematopoietic stem cells (HSCs) with long-term self-renewal capacity. After injury these cells are induced to proliferate to quickly re-establish homeostasis. The signalling molecules promoting the exit of HSCs out of the dormant stage remain largely unknown. Here we show that in response to treatment of mice with interferon-alpha (IFNalpha), HSCs efficiently exit G(0) and enter an active cell cycle. HSCs respond to IFNalpha treatment by the increased phosphorylation of STAT1 and PKB/Akt (also known as AKT1), the expression of IFNalpha target genes, and the upregulation of stem cell antigen-1 (Sca-1, also known as LY6A). HSCs lacking the IFNalpha/beta receptor (IFNAR), STAT1 (ref. 3) or Sca-1 (ref. 4) are insensitive to IFNalpha stimulation, demonstrating that STAT1 and Sca-1 mediate IFNalpha-induced HSC proliferation. Although dormant HSCs are resistant to the anti-proliferative chemotherapeutic agent 5-fluoro-uracil, HSCs pre-treated (primed) with IFNalpha and thus induced to proliferate are efficiently eliminated by 5-fluoro-uracil exposure in vivo. Conversely, HSCs chronically activated by IFNalpha are functionally compromised and are rapidly out-competed by non-activatable Ifnar(-/-) cells in competitive repopulation assays. Whereas chronic activation of the IFNalpha pathway in HSCs impairs their function, acute IFNalpha treatment promotes the proliferation of dormant HSCs in vivo. These data may help to clarify the so far unexplained clinical effects of IFNalpha on leukaemic cells, and raise the possibility for new applications of type I interferons to target cancer stem cells.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Essers, Marieke A G -- Offner, Sandra -- Blanco-Bose, William E -- Waibler, Zoe -- Kalinke, Ulrich -- Duchosal, Michel A -- Trumpp, Andreas -- England -- Nature. 2009 Apr 16;458(7240):904-8. doi: 10.1038/nature07815. Epub 2009 Feb 11.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Division of Stem Cells and Cancer, Deutsches Krebsforschungszentrum (DKFZ), DKFZ-ZMBH Alliance, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/19212321" target="_blank"〉PubMed〈/a〉
    Keywords: Animals ; Antigens, Ly/metabolism ; Cell Count ; Cell Cycle/*drug effects ; Cell Proliferation/drug effects ; Fluorouracil/pharmacology ; Hematopoietic Stem Cells/*cytology/*drug effects ; Interferon-alpha/*pharmacology ; Membrane Proteins/deficiency/metabolism ; Mice ; Mice, Inbred C57BL ; Phosphorylation/drug effects ; Receptor, Interferon alpha-beta/deficiency/metabolism ; STAT1 Transcription Factor/deficiency/metabolism ; Signal Transduction/drug effects ; Up-Regulation/drug effects
    Print ISSN: 0028-0836
    Electronic ISSN: 1476-4687
    Topics: Biology , Chemistry and Pharmacology , Medicine , Natural Sciences in General , Physics
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 3
    Publication Date: 2005-05-21
    Description: beta-Catenin is a multifunctional protein that mediates Wnt signaling by binding to members of the T cell factor (TCF) family of transcription factors. Here, we report an evolutionarily conserved interaction of beta-catenin with FOXO transcription factors, which are regulated by insulin and oxidative stress signaling. beta-Catenin binds directly to FOXO and enhances FOXO transcriptional activity in mammalian cells. In Caenorhabditis elegans, loss of the beta-catenin BAR-1 reduces the activity of the FOXO ortholog DAF-16 in dauer formation and life span. Association of beta-catenin with FOXO was enhanced in cells exposed to oxidative stress. Furthermore, BAR-1 was required for the oxidative stress-induced expression of the DAF-16 target gene sod-3 and for resistance to oxidative damage. These results demonstrate a role for beta-catenin in regulating FOXO function that is particularly important under conditions of oxidative stress.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Essers, Marieke A G -- de Vries-Smits, Lydia M M -- Barker, Nick -- Polderman, Paulien E -- Burgering, Boudewijn M T -- Korswagen, Hendrik C -- New York, N.Y. -- Science. 2005 May 20;308(5725):1181-4.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Department of Physiological Chemistry and Center for Biomedical Genetics, University Medical Center, Universiteitsweg 100, 3584 CG Utrecht, Netherlands.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/15905404" target="_blank"〉PubMed〈/a〉
    Keywords: Animals ; Animals, Genetically Modified ; Caenorhabditis elegans/genetics/*metabolism/physiology ; Caenorhabditis elegans Proteins/genetics/*metabolism ; Carrier Proteins/genetics/metabolism ; Cell Cycle ; Cell Line ; Cell Line, Tumor ; Cyclin-Dependent Kinase Inhibitor p27 ; Cytoskeletal Proteins/chemistry/genetics/*metabolism ; DNA-Binding Proteins/metabolism ; Forkhead Transcription Factors ; Humans ; Hydrogen Peroxide/pharmacology ; Immunoprecipitation ; Insulin/pharmacology ; Intracellular Signaling Peptides and Proteins/genetics/metabolism ; Lithium Chloride/pharmacology ; Longevity ; Mice ; Mutation ; *Oxidative Stress ; Receptor, Insulin/genetics/metabolism ; *Signal Transduction ; Superoxide Dismutase/metabolism ; Trans-Activators/chemistry/genetics/*metabolism ; Transcription Factors/*metabolism ; Transfection ; beta Catenin
    Print ISSN: 0036-8075
    Electronic ISSN: 1095-9203
    Topics: Biology , Chemistry and Pharmacology , Computer Science , Medicine , Natural Sciences in General , Physics
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 4
    Publication Date: 2015-02-25
    Description: Haematopoietic stem cells (HSCs) are responsible for the lifelong production of blood cells. The accumulation of DNA damage in HSCs is a hallmark of ageing and is probably a major contributing factor in age-related tissue degeneration and malignant transformation. A number of accelerated ageing syndromes are associated with defective DNA repair and genomic instability, including the most common inherited bone marrow failure syndrome, Fanconi anaemia. However, the physiological source of DNA damage in HSCs from both normal and diseased individuals remains unclear. Here we show in mice that DNA damage is a direct consequence of inducing HSCs to exit their homeostatic quiescent state in response to conditions that model physiological stress, such as infection or chronic blood loss. Repeated activation of HSCs out of their dormant state provoked the attrition of normal HSCs and, in the case of mice with a non-functional Fanconi anaemia DNA repair pathway, led to a complete collapse of the haematopoietic system, which phenocopied the highly penetrant bone marrow failure seen in Fanconi anaemia patients. Our findings establish a novel link between physiological stress and DNA damage in normal HSCs and provide a mechanistic explanation for the universal accumulation of DNA damage in HSCs during ageing and the accelerated failure of the haematopoietic system in Fanconi anaemia patients.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Walter, Dagmar -- Lier, Amelie -- Geiselhart, Anja -- Thalheimer, Frederic B -- Huntscha, Sina -- Sobotta, Mirko C -- Moehrle, Bettina -- Brocks, David -- Bayindir, Irem -- Kaschutnig, Paul -- Muedder, Katja -- Klein, Corinna -- Jauch, Anna -- Schroeder, Timm -- Geiger, Hartmut -- Dick, Tobias P -- Holland-Letz, Tim -- Schmezer, Peter -- Lane, Steven W -- Rieger, Michael A -- Essers, Marieke A G -- Williams, David A -- Trumpp, Andreas -- Milsom, Michael D -- England -- Nature. 2015 Apr 23;520(7548):549-52. doi: 10.1038/nature14131. Epub 2015 Feb 18.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH (HI-STEM), 69120 Heidelberg, Germany. ; Deutsches Krebsforschungszentrum (DKFZ), Division of Stem Cells and Cancer, Experimental Hematology Group, 69120 Heidelberg, Germany. ; LOEWE Center for Cell and Gene Therapy and Department of Hematology/Oncology, Goethe University Frankfurt, 60595 Frankfurt am Main, Germany. ; Deutsches Krebsforschungszentrum (DKFZ), DKFZ-ZMBH Alliance, Division of Redox Regulation, 69120 Heidelberg, Germany. ; Institute for Molecular Medicine, Stem Cells and Aging, Ulm University, 89081 Ulm, Germany. ; Deutsches Krebsforschungszentrum (DKFZ), Division of Stem Cells and Cancer, 69120 Heidelberg, Germany. ; Institute of Human Genetics, University of Heidelberg, 69120 Heidelberg, Germany. ; ETH Zurich, Department of Biosystems Science and Engineering, 4058 Basel, Switzerland. ; 1] Institute for Molecular Medicine, Stem Cells and Aging, Ulm University, 89081 Ulm, Germany [2] Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA. ; Deutsches Krebsforschungszentrum (DKFZ), Division of Biostatistics, 69120 Heidelberg, Germany. ; Deutsches Krebsforschungszentrum (DKFZ), Division of Epigenomics and Cancer Risk Factors, 69120 Heidelberg, Germany. ; QIMR Berghofer Medical Research Institute, University of Queensland, Brisbane 4006, Australia. ; 1] Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH (HI-STEM), 69120 Heidelberg, Germany [2] Deutsches Krebsforschungszentrum (DKFZ), Division of Stem Cells and Cancer, Hematopoietic Stem Cells and Stress Group, 69120 Heidelberg, Germany. ; 1] Boston Children's Hospital, Boston, Massachusetts 02115, USA [2] Dana-Faber Cancer Institute, Boston, Massachusetts 02115, USA [3] Harvard Stem Cell Institute, Boston, Massachusetts 02138, USA [4] Harvard Medical School, Boston, Massachusetts 02115, USA. ; 1] Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH (HI-STEM), 69120 Heidelberg, Germany [2] Deutsches Krebsforschungszentrum (DKFZ), Division of Stem Cells and Cancer, 69120 Heidelberg, Germany. ; 1] Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH (HI-STEM), 69120 Heidelberg, Germany [2] Deutsches Krebsforschungszentrum (DKFZ), Division of Stem Cells and Cancer, Experimental Hematology Group, 69120 Heidelberg, Germany.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/25707806" target="_blank"〉PubMed〈/a〉
    Keywords: Animals ; Bone Marrow/pathology ; *Cell Cycle ; Cell Death ; Cell Proliferation ; *DNA Damage ; Fanconi Anemia/metabolism ; Hematopoietic Stem Cells/*cytology/*metabolism ; Mice ; Reactive Oxygen Species/metabolism ; Stress, Physiological
    Print ISSN: 0028-0836
    Electronic ISSN: 1476-4687
    Topics: Biology , Chemistry and Pharmacology , Medicine , Natural Sciences in General , Physics
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 5
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...